Perturbing the cell death pathway for therapeutic benefit in cancer: Sounds like a good idea but does it work?

ORGN 325

Mark Lawler,, Institute of Molecular Medicine, Trinity College, Dublin, Ireland
There is a pressing need to identify new approaches which may fast-track the development of relevant anti-cancer agents. In many cancers, the apoptotic pathway is compromised, rendering malignant cells resistant to conventional chemotherapeutic regimens. Understanding apoptotic signalling processes in cancer cells can help unmask new targets for therapy. We have described a novel family of compounds which induce cell death in cancer cells, evading anti-apoptotic processes through perturbation of cellular architecture and modulation of death resistance proteins. Complementing our understanding of the mode of action of these compounds in cell line models, we have tested these agents in primary material from patients with malignancy (both treatment na´ve and treatment resistant), underlining their efficacy particularly in haematological malignancies. A precise evaluation of their mode of action in primary material also informs the development of more potent analogues and highlights their consideration as potential anti-cancer agents

Small Molecule Therapeutic Agents
8:30 AM-11:50 AM, Tuesday, August 18, 2009 Walter E. Washington Convention Center -- 207A, Oral

Division of Organic Chemistry

The 238th ACS National Meeting, Washington, DC, August 16-20, 2009